Jan Snoeys

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8818272/publications.pdf

Version: 2024-02-01

26 papers	1,724 citations	471509 17 h-index	552781 26 g-index
27 all docs	27 docs citations	27 times ranked	2802 citing authors

#	Article	IF	Citations
1	Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Scientific Reports, 2016, 6, 25187.	3.3	502
2	Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study. Toxicological Sciences, 2018, 162, 655-666.	3.1	219
3	Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nature Reviews Drug Discovery, 2020, 19, 131-148.	46.4	153
4	The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death. Toxicology in Vitro, 2015, 29, 732-740.	2.4	135
5	Advancing Predictions of Tissue and Intracellular Drug Concentrations Using InÂVitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. Clinical Pharmacology and Therapeutics, 2018, 104, 865-889.	4.7	92
6	Physiologicallyâ€Based Pharmacokinetic Models for Evaluating Membrane Transporter MediatedÂDrugâ€“Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations. Clinical Pharmacology and Therapeutics, 2020, 107, 1082-1115.	4.7	88
7	Amino acid levels determine metabolism and CYP450 function of hepatocytes and hepatoma cell lines. Nature Communications, 2020, 11, 1393.	12.8	79
8	Drugâ€“Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir. Clinical Pharmacokinetics, 2016, 55, 197-208.	3.5	65
9	Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: In vitro, rat in situ and human in vivo studies. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 90, 1-7.	4.3	62
10	Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. Archives of Toxicology, 2016, 90, 2979-3003.	4.2	50
11	High-throughput confocal imaging of differentiated 3D liver-like spheroid cellular stress response reporters for identification of drug-induced liver injury liability. Archives of Toxicology, 2019, 93, 2895-2911.	4.2	40
12	The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man. Journal of Pharmaceutical Sciences, 2016, 105, 2974-2981.	3.3	36
13	The utility of HepaRG cells for bioenergetic investigation and detection of drug-induced mitochondrial toxicity. Toxicology in Vitro, 2018, 53, 136-147.	2.4	33
14	Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 767-782.	3.3	30
15	Short-term supplementation of celecoxib-shifted butyrate production on a simulated model of the gut microbial ecosystem and ameliorated in vitro inflammation. Npj Biofilms and Microbiomes, 2020, 6, 9.	6.4	24
16	In Vitro Model for Hepatotoxicity Studies Based on Primary Human Hepatocyte Cultivation in a Perfused 3D Bioreactor System. International Journal of Molecular Sciences, 2016, 17, 584.	4.1	19
17	In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. Drug Metabolism and Disposition, 2016, 44, 1682-1691.	3.3	18
18	Development of an LCâ€“MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1073, 80-89.	2.3	12

#	Article	IF	Citations
19	Acute Metabolic Switch Assay Using Glucose/Galactose Medium in HepaRG Cells to Detect Mitochondrial Toxicity. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2019, 80, e76.	1.1	12
20	Insight into the colonic disposition of celecoxib in humans. European Journal of Pharmaceutical Sciences, 2020, 145, 105242.	4.0	12
21	A physiologically based pharmacokinetic modeling approach to predict drugâ€“drug interactions between domperidone and inhibitors of CYP3A4. Biopharmaceutics and Drug Disposition, 2016, 37, 15-27.	1.9	10
22	Insight into the Colonic Disposition of Sulindac in Humans. Journal of Pharmaceutical Sciences, 2021, 110, 259-267.	3.3	9
23	Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics, 2017, 56, 781-792.	3.5	8
24	The utility of a differentiated preclinical liver model, HepaRG cells, in investigating delayed toxicity via inhibition of mitochondrial-replication induced by fialuridine. Toxicology and Applied Pharmacology, 2020, 403, 115163.	2.8	8
25	Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of In Vitro Models. Applied in Vitro Toxicology, 2015, 1, 175-186.	1.1	5
26	Effect of Plasma Protein Binding on the Anti-Hepatitis B Virus Activity and Pharmacokinetic Properties of NVR 3-778. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	3